Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients?
about
Overactive bladder in the vulnerable elderlyEfficacy of propiverine ER with or without α-blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional study.Pathogens in Urine from a Female Patient with Overactive Bladder Syndrome Detected by Culture-independent High Throughput Sequencing: A Case ReportPostmenopausal overactive bladderObservational study on safety and tolerability of duloxetine in the treatment of female stress urinary incontinence in German routine practice.Factors associated with efficacy of an ibuprofen/pseudoephedrine combination drug in pharmacy customers with common cold symptoms.Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: lack of anticholinergic efficacy versus intolerability.Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.Management of OAB in those over age 65.Urinary incontinence in men: current and developing therapy options.Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies.Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?Patient factors associated with onabotulinum toxin A treatment outcome in women with detrusor overactivity.Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome.Does concomitant diabetes affect treatment responses in overactive bladder patients?Antimuscarinic agents in elderly people.Nocturia in patients with benign prostatic hyperplasia: evaluating the significance of ageing, co-morbid illnesses, lifestyle and medical therapy in treatment outcome in real life practice
P2860
Q34351806-DBFFA050-38A6-43CD-AB49-D069020E8219Q34709479-B81E7205-4618-4578-AA78-648D49EEB506Q35070550-C444762B-6B28-4526-B772-618F97F675AFQ35157329-647F2EE9-8F8B-48F6-8F49-52D187142DE7Q36729973-1D06E338-0A57-4ED1-926F-DDDC2BCDF352Q37696442-53EA768A-5B7D-4188-8078-1150A76488EDQ37914098-CC682F91-E7B1-4784-A364-3D84D52C24D8Q38032608-0F785B04-A1EA-4F23-B796-170FF5F2E653Q38127155-4F4DC9C1-C2C7-43FB-8BE8-DBEDC125609BQ38708104-2931E440-138D-44F3-ABAB-77B9030B6E4BQ38765381-5C7D3FB1-FE68-48AA-9642-98EFBC0283BEQ39412362-2826E8C9-E91D-4C98-97CE-1D403176F6FFQ40118662-AA5689D2-F761-4DDD-B5FF-B88239BF4765Q43815698-7776471C-8C0D-4FA7-8248-96135C7CEAD1Q46189177-0AF8FC51-9106-4D91-B132-157984EFC45AQ51037347-402F366F-FD05-4BEA-B73C-0FDCE21A1639Q58269335-7F451E4D-3F8D-4BFA-8CB2-015D023E7F85
P2860
Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients?
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Do gender, age or lifestyle fa ...... n overactive bladder patients?
@en
Do gender, age or lifestyle fa ...... n overactive bladder patients?
@nl
type
label
Do gender, age or lifestyle fa ...... n overactive bladder patients?
@en
Do gender, age or lifestyle fa ...... n overactive bladder patients?
@nl
prefLabel
Do gender, age or lifestyle fa ...... n overactive bladder patients?
@en
Do gender, age or lifestyle fa ...... n overactive bladder patients?
@nl
P2093
P2860
P1476
Do gender, age or lifestyle fa ...... n overactive bladder patients?
@en
P2093
D Marschall-Kehrel
J U Hanisch
M C Michel
T Schneider
P2860
P304
P356
10.1111/J.1742-1241.2010.02442.X
P577
2010-05-24T00:00:00Z